Is Synergen The Next Amgen?

When the attempted Gorbachev ouster hammered down the Dow by 100 points on the morning of Aug. 19, investment manager Warren Greene snapped up shares of Synergen as they tumbled nearly 2 points, to 39 1/2 a share. No, Synergen isn't in the defense business; it's a biotech stock that Greene had been buying for weeks at higher prices, so when it slumped, he jumped at the chance of buying more. By Aug. 21, Synergen had rebounded to 44.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.